Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scrip 100: Chugai USA's new CMO is a Man for All Regions

This article was originally published in Scrip

Executive Summary

When the Swiss-born and transatlantic-bred Dr Athos Gianella-Borradori took up his new role as Chugai Pharma USA's chief medical officer in April, an international perspective was vital. So he took for his inspiration Carlos Goshn, the French-Lebanese-Brazilian businessman famous for turning round the Japanese car maker Nissan. As one of the first non-Japanese CEOs of a very traditional Japanese company, Goshn was the perfect role model in a job that would demand high levels of cultural awareness.

You may also be interested in...



Moderna Wins Bivalent COVID-19 Vaccine Booster Race With First Approval

Moderna takes the next step in the in the development of COVID-19 vaccines, with the first approval of the first bivalent vaccine that can produce a broader immune response to new SARS-CoV-2 variants.

New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data

The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.

AZ’s Susan Galbraith On What’s Next In The Cancer Pipeline

One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to In Vivo about what’s coming next from the UK major’s cancer pipeline.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC026534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel